Founded in 2011 by scientist and entrepreneur Liping Liu, HighTide Therapeutics is a biopharmaceutical company developing multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic diseases. Its lead candidate, HTD1801, is an oral metabolic modulator built from berberine and ursodeoxycholic acid and is being evaluated in global clinical programs. HighTide also maintains an early-stage research portfolio spanning acute inflammatory disease, weight modulation and neurodegenerative conditions.
National High-Tech Enterprise of China
Innovative Small and Medium-sized Enterprise (SME)
First batch of Strategic Enterprise Partners of the Hong Kong SAR Government
Registration
FDA Fast Track Designation for HTD1801
FDA Orphan Drug Designation for HTD1801
CorvidaneCorvidane is a privately held life sciences company developing patented therapeutic programmes for complex cardiometabolic diseases, including atherosclerosis and MASH. Co-founded by Damion J. Boyer and chemical engineer John M. Burke, the company takes a biology-driven approach aimed at addressing interconnected lipid, inflammatory, and fibrotic disease processes rather than a single target. Its lead programme, CVMB-216, is being advanced through structured preclinical development toward regulated clinical pathways and potential partnerships.NETHERLANDS &, NY
Tactical TherapeuticsFounded in 2005 by cancer scientist and patent attorney Rashida A. Karmali, Tactical Therapeutics is a clinical-stage biopharmaceutical company built around her long career in cancer research, drug development, and intellectual property law. The company develops CTO, an oral therapy designed to reach the brain, for patients with glioblastoma and other cancers that have resisted treatment. Karmali has authored more than 100 scientific publications and holds eight U.S. patents alongside more than 75 international patents.NEW YORK, NY
Axsome Therapeutics, IncFounded in January 2012 by physician Herriot Tabuteau, Axsome Therapeutics is a New York biopharmaceutical company focused on central nervous system conditions with limited treatment options. Its work centers on developing therapies intended to give patients and physicians new approaches where existing care falls short.NEW YORK, NY
Nuvation BioFounded in 2018 by biopharma veteran David Hung, M.D., Nuvation Bio develops and commercializes oncology medicines for difficult-to-treat cancers. The company’s portfolio includes the FDA-approved therapy IBTROZI® (taletrectinib) and investigational treatments supported by global clinical programs, with offices in the United States and China.New York, NY